Selskabets formål er at forske, udvikle, producere og sælge, herunder gennem ind- og udlicensering, produkter, processer, teknologier, service og andre beslægtede forretningsområder efter bestyrelsens skøn.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2025 | 593.8 mio. | 39.1 mio. | 390.9 mio. | 162.9 mio. | 159 | |
CVR: 10013267
Secondary names: Symphogen A/S
Compared to 1.003 companies in Forskning og eksperimentel udvikling inden for naturvidenskab og teknik
Comparison is based on industry median values
Servier Symphogen A/S demonstrates a strong recovery in financial health, with significant growth in revenue and profit over the past few years. Revenue surged from 70 million DKK in 2022 to nearly 594 million DKK in 2025, while profit has remained relatively stable, increasing from 37 million DKK in 2024 to 39 million DKK in 2025. However, the equity position has seen fluctuations, dropping to 162 million DKK in 2025 from 223 million DKK in 2024, indicating potential concerns regarding long-term sustainability. The company is positioned well within the research and experimental development sector, showcasing resilience and growth potential despite past equity challenges.
AI-generated summary
Companies in the same industry and area
CVR 43901885
CVR 45796256
CVR 21142743
CVR 32252397
CVR 34724938
companydata.dk